论文部分内容阅读
目的：研究卵巢的子宫内膜样癌ｐ５３基因蛋白、增殖细胞核抗原（ＰＣＮＡ）的表达与ＤＮＡ倍体分析之间的相互关系，并对其与临床分期、病理学分级与残存瘤的关系等进行分析、比较。方法：应用流式细胞技术及ｐ５３、ＰＣＮＡ单克隆抗体免疫组化技术对卵巢的子宫内膜样癌１３例进行倍体分析及基因、抗原测定。结果：ＤＮＡ异倍体率为７８％，ｐ５３基因蛋白表达率为４６％，ＰＣＮＡ表达率为９２％。ＤＮＡ倍体分析与临床Ⅱ～Ⅳ期、病理２～３级及残存瘤＞２ｃｍ者有关，异倍体阳性率分别为９０．９％、８８．８％、８７．５％，明显高于临床Ⅰ期、病理１级及无残存瘤者。ｐ５３在临床Ⅱ～Ⅳ期、病理２～３级表达率分别为６８．６％和５５．５％，均高于临床Ⅰ期及病理１级者，并对ＤＮＡ倍体水平与ｐ５３表达之间的关系进行了探讨。结论：ＤＮＡ异倍体与ｐ５３基因蛋白表达阳性可作为卵巢的子宫内膜样癌恶性程度的重要指标。
Objective: To study the relationship between the expression of p53 gene protein, proliferating cell nuclear antigen (PCNA) and DNA ploidy analysis in ovarian endometrioid carcinoma, and to study the relationship between the clinical stage, pathological grade and residual tumor. analyse and compare. METHODS: Fifteen cases of ovarian endometrioid carcinoma were analyzed by flow cytometry and p53 and PCNA monoclonal antibody immunohistochemistry for ploidy analysis and gene and antigen detection. Results: The DNA aneuploidy rate was 78%, the p53 gene protein expression rate was 46%, and the PCNA expression rate was 92%. DNA ploidy analysis was associated with clinical stages II-IV, pathological grades 2-3, and residual tumors >2 cm. The positive rate of aneuploidy was 90.9%, 88.8%, and 87.5%, respectively. Stage I, pathological grade 1 and no residual tumor. The expression rates of p53 in clinical stage II-IV and pathological stage 2-3 were 68.6% and 55.5%, respectively, which were higher than those in clinical stage I and pathological grade 1, and between DNA ploidy and p53 expression. The relationship was explored. Conclusion: The positive expression of DNA aneuploid and p53 gene can be used as an important indicator of malignancy of ovarian endometrioid carcinoma.